Sector consensus Arrowhead Pharmaceuticals, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 18/07/2025 BST			5-day change	1st Jan Change
16.76 ^USD	-11.09%		-8.47%	-10.85%

07-08	Arrowhead Pharmaceuticals, Inc., Q2 2025 Earnings Call, May 12, 2025
07-08	Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Average Target P.	Ecart obj. / dr	Nbr of analysts
ARROWHEAD PHARMACEUTICALS, INC.	US$44	+162.53%	14
ARGENX SE	€665.23	+35.21%	14
WUXI APPTEC CO., LTD.	CN¥83.73	+1.37%	18
BIONTECH SE	US$116.18	+23.07%	21
INSMED INCORPORATED	US$113.55	+10.72%	18
SUMMIT THERAPEUTICS INC.	US$25.7	+32.01%	9
AKESO, INC.	HK$104.36	-18.92%	20
WUXI BIOLOGICS (CAYMAN) INC.	HK$27.52	+5.33%	26
GENMAB A/S	DKK 1,928.76	+35.88%	16
EXELIXIS, INC.	US$45.89	+3.2%	19
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	HK$330.26	-15.01%	16
VERONA PHARMA PLC	US$106.22	+1.26%	9
LEGEND BIOTECH CORPORATION	US$76.29	+83.43%	19
MADRIGAL PHARMACEUTICALS, INC.	US$425	+27.2%	14
PHARMAESSENTIA CORPORATION	NT$690.5	+26%	4
SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.	CN¥99.04	-0.07%	2
BIOCON LIMITED	₹382.9	-3.97%	20
NUVALENT, INC.	US$117.3	+40.65%	10
REMEGEN CO., LTD.	HK$39.92	-38.34%	14
Average	285.39	+21.66%	15
Weighted average by Cap.	300.4	+16.52%	16